News Sentiment

JNJ sentiment intelligence

Johnson & Johnson news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors Options RSS feed
Weighted score 55 Balanced news tone 57 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Drug Manufacturers - General Read-through group
Latest close 256.98 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 57

directly relevant articles

Source quality 6

high-authority source matches

Trend context Trend active

-2.3% over one week, +6.7% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Goldman Sachs Adjusts Price Target on Johnson & Johnson to $282 From $275, Maintains Buy Rating

Market Reaction

Balanced read

63/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction -2.3% Price reacting lower
Trend fit Trend active 6.7% over four weeks
Fair value 52.4% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 22
Neutral 31
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 57
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
MarketBeat 13
MT Newswires 9
Market source 8
simplywall.st 5
Morningstar 2
Barron's 2
BioSpace 2
Fierce Biotech 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 16
Analyst action 9
Guidance 2
Macro sensitivity 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-57 of 57
The Manila Times Direct company coverage

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026

Genmab announced that worldwide net trade sales of DARZALEX (daratumumab) for the second quarter of 2026 totaled USD 4,207 million. This figure includes sales of both intravenous and subcutaneous products, as reported by Johnson & Johnson. Genmab receives royalties on these globa

Tone
Positive 72/100
Event
Earnings
Published
15 Jul 2026 10:40
Source
The Manila Times
Barron's Direct company coverage

Johnson & Johnson Hikes Guidance, Stock Falls

Johnson & Johnson exceeded second-quarter earnings and revenue expectations, prompting the company to raise its full-year guidance. This growth was primarily driven by the strong performance of its oncology portfolio, despite a decline in sales for its drug, Stelara. Despite the

Tone
Neutral 50/100
Event
Earnings
Published
15 Jul 2026 10:34
Source
Barron's
WSJ Direct company coverage

Johnson & Johnson Bumps Up Guidance as Sales Rise

Johnson & Johnson has raised its full-year guidance for sales and adjusted earnings per share after reporting higher sales in the latest quarter. The company now expects full-year sales of $100.8 billion to $101.4 billion and adjusted earnings per share between $11.60 to $11.75,

Tone
Positive 74/100
Event
Earnings
Published
15 Jul 2026 10:32
Source
WSJ
Reuters Direct company coverage

J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

Johnson & Johnson surpassed Wall Street expectations for its second-quarter sales and profit, primarily driven by strong performance in its pharmaceutical unit, particularly from Darzalex and Tremfya. The company also raised its full-year sales and profit outlook, despite a sligh

Tone
Positive 72/100
Event
Earnings
Published
15 Jul 2026 10:27
Source
Reuters
MarketBeat Direct company coverage

LGT Fund Management Co Ltd. Grows Stake in Johnson & Johnson $JNJ

LGT Fund Management Co Ltd. significantly increased its stake in Johnson & Johnson (NYSE:JNJ) by 770.7% in the first quarter, now owning 112,310 shares valued at $27.45 million. Other institutional investors have also adjusted their holdings, while Johnson & Johnson's stock is tr

Tone
Positive 66/100
Event
Earnings
Published
15 Jul 2026 09:15
Source
MarketBeat